iBio to Participate in Upcoming Healthcare Investor Conferences

Rhea-AI Summary

iBio (NASDAQ: IBIO) announced participation in two upcoming healthcare investor conferences. CEO/CSO Martin Brenner and CFO Felipe Duran will present and hold investor meetings.

The events include the Jefferies Global Healthcare Conference on June 4, 2026, in New York and the Leerink Partners Therapeutics Forum on July 14–15, 2026, in Boston.

News Market Reaction – IBIO

+4.55%

8 alerts

+4.55% Session close to close

+5.7% Peak Tracked

-2.3% Trough Tracked

$91.91M Market Cap

1.0x Rel. Volume

In the Jun 3 session, IBIO gained 4.55%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.7% during that session. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights IBIO’s participation in the Jefferies Global Healthcare Conference on J...

Analysis

This announcement highlights IBIO’s participation in the Jefferies Global Healthcare Conference on June 4, 2026 and the Leerink forum on July 14–15, 2026, with a webcast replay available for 90 days. These events extend the company’s pattern of active investor communication following recent clinical and financial updates. Investors may track how messaging at these conferences aligns with prior disclosures and funding flexibility under the existing shelf registration.

Key Figures

Jefferies presentation date: June 4, 2026 Jefferies presentation time: 11:40 a.m. ET Webcast replay duration: 90 days +1 more

4 metrics

Jefferies presentation date June 4, 2026 Jefferies Global Healthcare Conference presentation

Jefferies presentation time 11:40 a.m. ET Scheduled presentation slot at Jefferies conference

Webcast replay duration 90 days Replay availability on Investor Relations website

Leerink forum dates July 14–15, 2026 Leerink Partners Therapeutics Forum: I&I and Metabolism

Historical Context

5 past events · Latest: May 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 12	Earnings and update	Neutral	-3.7%	Q3 FY2026 results plus obesity pipeline and cash runway update.
May 08	Board appointment	Positive	+4.3%	Addition of experienced biotech leader to board and committee.
Apr 08	Clinical trial clearance	Positive	+6.2%	Regulatory and ethics clearance for Phase 1 IBIO-600 trial.
Mar 16	Program update	Positive	+2.9%	Upcoming call on PH-HFpEF program and bispecific antibody plans.
Mar 09	Preclinical data	Positive	-4.2%	IBIO-610 obese NHP data with fat reductions and long half-life.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Most prior catalysts with clear positive developments saw aligned positive price moves, with occasional divergence on strong preclinical data.

Recent Company History

Over the last few months, IBIO has reported multiple development milestones, including Phase 1 clearance for IBIO-600 in April 2026 and positive IBIO-610 preclinical data in March 2026. A Q3 FY2026 update on May 12 detailed zero revenue but a strengthened cash position and extended runway. Management and program updates in March and May also shaped expectations. Today’s conference-participation news fits a pattern of frequent corporate communications alongside pipeline progress.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference.

Jefferies Global Healthcare Conference
Presentation Date: Thursday, June 4, 2026
Time: 11:40 a.m. ET
Location: Marriott Marquis, New York

A livestream of the event can be accessed link, and a replay of the presentation webcast will be available on the Investor Relations section of the iBio website for 90 days following the event.

Leerink Partners Therapeutics Forum: I&I and Metabolism
Event Dates: July 14–15, 2026
Location: Boston Harbor Hotel, Boston

Dr. Brenner and Mr. Duran will participate in one-on-one investor meetings during the Leerink conference. Preliminary meeting schedules are expected to be available in mid-June.

To request a meeting with Dr. Brenner or Mr. Duran at either conference, please contact ir@ibioinc.com.

About iBio, Inc.

iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.

Contact:

iBio, Inc. 
Investor Relations 
ir@ibioinc.com

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

FAQ

When will iBio (NASDAQ: IBIO) present at the Jefferies Global Healthcare Conference 2026?

iBio will present at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 11:40 a.m. ET. According to iBio, the session takes place at the Marriott Marquis in New York and will also be available via livestream and webcast replay.

How can investors access the iBio (IBIO) Jefferies 2026 conference webcast?

Investors can access a livestream of iBio’s Jefferies Global Healthcare Conference presentation online. According to iBio, a replay of the webcast will be available for 90 days on the company’s Investor Relations section after the June 4, 2026 presentation.

What are the dates and location of the Leerink Partners Therapeutics Forum featuring iBio (IBIO)?

iBio will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 14–15, 2026. According to iBio, the event will be held at the Boston Harbor Hotel in Boston, where the company’s executives will attend investor meetings.

Will iBio management hold one-on-one investor meetings at the Leerink Partners 2026 forum?

Yes, iBio management plans to participate in one-on-one investor meetings during the Leerink Partners Therapeutics Forum. According to iBio, Dr. Martin Brenner and Felipe Duran will meet investors, with preliminary schedules expected in mid-June 2026.

How can investors request a meeting with iBio (IBIO) management at the 2026 conferences?

Investors can request meetings with iBio’s executives by emailing the company’s investor relations contact. According to iBio, meeting requests for both the Jefferies and Leerink conferences should be sent to ir@ibioinc.com for scheduling consideration.

Who will represent iBio (IBIO) at the Jefferies and Leerink healthcare conferences in 2026?

iBio will be represented by CEO and Chief Scientific Officer Dr. Martin Brenner and Chief Financial Officer Felipe Duran. According to iBio, both executives will participate in the Jefferies presentation and investor meetings at the Leerink Partners forum.